Last reviewed · How we verify
AZD9150
AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein.
AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein. Used for Advanced solid tumors, including lymphoma and multiple myeloma.
At a glance
| Generic name | AZD9150 |
|---|---|
| Also known as | STAT3 inhibitor, ISIS 481464 |
| Sponsor | Acerta Pharma BV |
| Drug class | antisense oligonucleotide |
| Target | MYC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to the mRNA of the MYC oncogene, AZD9150 prevents the translation of MYC protein, which is often overexpressed in various cancers. This reduction in MYC protein levels can inhibit tumor growth and proliferation.
Approved indications
- Advanced solid tumors, including lymphoma and multiple myeloma
Common side effects
- Thrombocytopenia
- Neutropenia
Key clinical trials
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (PHASE1)
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (PHASE1, PHASE2)
- Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PHASE2)
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML (PHASE1)
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (PHASE2)
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer (PHASE2)
- AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9150 CI brief — competitive landscape report
- AZD9150 updates RSS · CI watch RSS
- Acerta Pharma BV portfolio CI